Microfluidic Cell Transfection via Electric Field and Unsteady Flow
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for intracellular delivery of exogenous materials, such as CAR-T cell therapies, face challenges with low cell recovery rates, viability, and throughput, as well as alterations in cell function and activation markers, particularly with electroporation, which limits their effectiveness and scalability in gene-modified cell therapy manufacturing.
Innovation Solution
A method involving exposure to an electric field and unsteady flow to facilitate the introduction of exogenous materials into cells using a microfluidic device with electrodes and flow diverters, which enhances delivery efficiency while minimizing cell perturbation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If electroporation is used for intracellular delivery of exogenous materials, then delivery efficiency is improved, but cell recovery rate and viability deteriorate
Solution Approach 1:
The patent segments the delivery process into distinct stages: cells first pass through a high-voltage electroporation zone for membrane permeabilization, then immediately enter a low-voltage recovery zone. This spatial segmentation allows efficient delivery while providing a dedicated recovery environment, resolving the contradiction between delivery efficiency and cell viability
Solution Approach 2:
The patent applies preliminary action by pre-cooling cells to 4°C before electroporation to reduce metabolic activity and minimize stress damage. Additionally, the recovery zone is prepared in advance with optimal conditions (low voltage, specific media) to immediately support cell recovery after the harsh electroporation event, thereby improving cell recovery rates while maintaining delivery efficiency
2Manufacturing precision
If electroporation is used for intracellular delivery, then delivery efficiency is improved, but cell function and activation markers are altered
Solution Approach 1:
The patent separates the electroporation event from the cell recovery and functional assessment phases by creating distinct electrical zones. The high-voltage zone is confined to a small region, and cells immediately transition to a low-voltage recovery zone, limiting the duration and spatial extent of electrical stress on cells, thereby reducing alterations to cell function and activation markers
Solution Approach 2:
The patent implements beforehand cushioning by providing a low-voltage recovery zone immediately after the high-voltage electroporation zone. This recovery zone acts as a buffer that allows cells to stabilize and recover from the electrical stress before entering subsequent processing or functional assessment, thereby minimizing harmful alterations to cell function
3Reliability
If conventional microfluidic methods are used for intracellular delivery, then cell viability is improved, but throughput and processing speed deteriorate
Solution Approach 1:
The patent implements continuous flow electroporation where cells move continuously through the device at controlled speeds, eliminating the need for batch processing and manual operations. The continuous flow through the electroporation zone maintains cell viability through gentle hydrodynamic forces while achieving high throughput by processing large numbers of cells simultaneously in a single pass
Solution Approach 2:
The patent uses hydrodynamic forces and pressure gradients to drive continuous cell flow through the electroporation device. This hydraulic approach enables high-throughput processing by maintaining steady, controlled cell movement through the treatment zone, achieving both high viability through gentle handling and high throughput through continuous processing
4Manufacturing precision
If viral transduction is used for CAR-T cell generation, then delivery efficiency is improved, but manufacturing complexity and safety testing requirements increase
Solution Approach 1:
The patent replaces the biological viral transduction system with a physical electroporation-based delivery system. This substitution eliminates the need for viral vector production, purification, and safety testing while achieving comparable or superior delivery efficiency. The mechanical/electrical system is simpler to manufacture and regulate than complex viral production facilities
Solution Approach 2:
The patent employs disposable electroporation cartridges or microfluidic chips that are pre-configured with electrodes and flow channels. These single-use components eliminate the need for complex sterilization and validation procedures required for reusable viral transduction equipment, reducing manufacturing complexity while maintaining delivery efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves cell recovery, viability, and expression efficiency, achieving high yields of viable and functional cells with even expression profiles across T cell subtypes, and maintains normal cell activation states, thus addressing the limitations of existing intracellular delivery methods.
Implementation Method 1
exposing the cell to an electric field, in the presence of the exogenous material
Implementation Method 2
exposing the cell to unsteady flow
Data Source
AI summary
A method and device for transfecting a cell to introduce an exogenous material into the cell. The method includes exposing the cell to a region of unsteady flow in the presence of an electric field to encourage introduction of the exogenous material into a cell without lysing the cell.